n | % | ||
---|---|---|---|
Total | 43 | 100 | |
Age | Median | 54 | --- |
Range | 19-74 | --- | |
Gender | Male | 26 | 60.5 |
Female | 17 | 39.5 | |
ECOG PS | 0 | 7 | 16.3 |
1 | 30 | 69.8 | |
2 | 6 | 14.0 | |
Histology | Leiomyosarcoma | 9 | 20.9 |
Angiosarcoma | 6 | 14.0 | |
MFH/UPS | 5 | 11.6 | |
MPNST | 5 | 11.6 | |
Fibroblastic tumor | 4 | 9.3 | |
Synovial sarcoma | 4 | 9.3 | |
Rhabdomyosarcoma | 3 | 7.0 | |
Liposarcoma | 2 | 4.7 | |
Tumor of uncertain differentiation | 3 | 7.0 | |
Desmoplastic small cell tumor | 1 | 2.3 | |
PEComa | 1 | 2.3 | |
FNCLCC grade | 1 | 3 | 7.0 |
2 | 6 | 14.0 | |
3 | 13 | 30.2 | |
unknown | 21 | 48.8 | |
Primary site | Trunk or retroperitoneum | 34 | 79.1 |
Extremity | 9 | 20.9 | |
Organ involvement | Lung | 32 | 74.4 |
Liver | 12 | 27.9 | |
Bone | 17 | 39.5 | |
Number of prior chemotherapy regimens chemotherapies | 1 | 9 | 20.9 |
2 | 15 | 34.9 | |
≥3 | 19 | 44.2 | |
Agents used in prior regimen(s) | Doxorubicin | 30 | 69.8 |
Ifosfamide | 39 | 90.7 | |
Taxane | 32 | 74.4 | |
Gemcitabine | 28 | 65.1 | |
Dacarbazine | 6 | 14.0 | |
Cycles of pazopanib treatment | Median | 4.8 | --- |
Range | 1-17 | --- |